Why the study?
Does a microfluidic chip method detect alterations in HDL2b subfractions in non-obese patients with type 2 diabetes compared to matched controls?
Does a microfluidic chip method detect alterations in HDL2b subfractions in non-obese patients with type 2 diabetes compared to matched controls?
A novel microfluidic chip method demonstrates reduced HDL2b levels in non-obese T2DM patients, which correlates with insulin resistance.
Microfluidic detection of reduced HDL2b in non-obese T2DM supports its association with insulin resistance; leaves open clinical utility pending prospective validation.
BACKGROUND: Alterations in high-density lipoprotein (HDL) subfractions, especially in the HDL2b subfraction, have been reported in type 2 diabetes mellitus (T2DM). However, new methods for convenient and reliable quantitation of HDL2b are yet to be developed. METHODS: Thirty-eight patients with T2DM were enrolled and age-, sex- and body mass index (BMI)-matched controls were selected from the same population. A microfluidic chip method was employed to analyse serum HDL subfractions. RESULTS: The microfluidic chip method revealed a significant reduction in HDL2b and its ratio to total HDL in T2DM patients. There was a reverse correlation for total HDL and HDL2b, and its ratio with triglycerides, homeostasis model assessment-insulin sensitivity index (HOMA-IS) and insulin resistance index (HOMA-IR). CONCLUSIONS: We have shown a reduction of HDL2b and its ratio to total HDL by a novel chip method in T2DM patients. The significant correlation between HDL2b and HOMA-IS and HOMA-IR may have further predictive value in clinical utility.
No takes yet. Share an insight, caveat, or question.
Xian et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: